[go: up one dir, main page]

WO2004041065A3 - METHODS FOR PROPHYLAXIS AND TREATMENT OF HER-2/neu TUMORS - Google Patents

METHODS FOR PROPHYLAXIS AND TREATMENT OF HER-2/neu TUMORS Download PDF

Info

Publication number
WO2004041065A3
WO2004041065A3 PCT/US2003/034362 US0334362W WO2004041065A3 WO 2004041065 A3 WO2004041065 A3 WO 2004041065A3 US 0334362 W US0334362 W US 0334362W WO 2004041065 A3 WO2004041065 A3 WO 2004041065A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
dendritic cells
neu
prophylaxis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/034362
Other languages
French (fr)
Other versions
WO2004041065A2 (en
Inventor
John J Morris
Jay A Berzofsky
Yoshio Sakai
Jong-Myun Park
Masake Terabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Priority to AU2003286770A priority Critical patent/AU2003286770A1/en
Publication of WO2004041065A2 publication Critical patent/WO2004041065A2/en
Publication of WO2004041065A3 publication Critical patent/WO2004041065A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention provides for methods for vaccination of dendritic cells, modified by recombinant adenoviral vectors (rAds) expressing truncated HER2/neu genes. Infection of dendritic cells with recombinant adenoviral vectors increases the expression of the DC surface maturation markers CD80, CD86, MHC-class I, II; and CD40 and spontaneous breast cancers were delayed or prevented by vaccination with dendritic cells genetically modified by recombinant adenoviruses expressing a non-signaling HER2/neu antigen.
PCT/US2003/034362 2002-10-30 2003-10-29 METHODS FOR PROPHYLAXIS AND TREATMENT OF HER-2/neu TUMORS Ceased WO2004041065A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003286770A AU2003286770A1 (en) 2002-10-30 2003-10-29 METHODS FOR PROPHYLAXIS AND TREATMENT OF HER-2/neu TUMORS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42239502P 2002-10-30 2002-10-30
US60/422,395 2002-10-30

Publications (2)

Publication Number Publication Date
WO2004041065A2 WO2004041065A2 (en) 2004-05-21
WO2004041065A3 true WO2004041065A3 (en) 2005-03-24

Family

ID=32312500

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/034362 Ceased WO2004041065A2 (en) 2002-10-30 2003-10-29 METHODS FOR PROPHYLAXIS AND TREATMENT OF HER-2/neu TUMORS

Country Status (2)

Country Link
AU (1) AU2003286770A1 (en)
WO (1) WO2004041065A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2397249C2 (en) * 2003-07-21 2010-08-20 Иституто Ди Ричерке Ди Биолоджиа Молеколаре П Анджелетти Спа NUCLEIC ACID SYNTHETIC MOLECULE (VERSIONS), MAMMAL CELL EXPRESSION VECTOR, MAMMAL HOST CELL AND METHOD OF EXPRESSING ANTIGEN PROTEIN OF HUMAN EPIDERMAL GROWTH FACTOR-2 (HER2/neu) OR SHORTENED FORM THEREOF
ITMI20041965A1 (en) * 2004-10-15 2005-01-15 Augusto Amici "CODIFYING DYNAMIC AND CHEMICAL FORMS OF PROTEIN P185NEU AND ITS THERAPEUTIC USES"
US11266726B2 (en) 2015-10-30 2022-03-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for the treatment of HER2-expressing solid tumors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020039573A1 (en) * 2000-01-21 2002-04-04 Cheever Martin A. Compounds and methods for prevention and treatment of HER-2/neu associated malignancies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020039573A1 (en) * 2000-01-21 2002-04-04 Cheever Martin A. Compounds and methods for prevention and treatment of HER-2/neu associated malignancies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AMICI ET AL.: "DNA vaccination with full-length or truncated Neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice", GENE THERAPY, vol. 7, 2000, pages 703 - 706, XP002314634 *
IKUTA ET AL.: "Presentation of a major histocompatibility complex class 1-binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharide-truncat3ed HER2 protein complex: implications for a polyvalent immuno-cell therapy", BLOOD, vol. 99, no. 10, May 2002 (2002-05-01), pages 3717 - 3724, XP002983121 *
SHIKU ET AL.: "Development of a cancer vaccine: peptides, proteins, and DNA", CANCER CHEMOTHER. PHARMACOL., vol. 46, 2000, pages S77 - S82, XP002908597 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists

Also Published As

Publication number Publication date
WO2004041065A2 (en) 2004-05-21
AU2003286770A1 (en) 2004-06-07
AU2003286770A8 (en) 2004-06-07

Similar Documents

Publication Publication Date Title
Sakai et al. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice
AU4078599A (en) Expression vectors for stimulating an immune response and methods of using the same
EP2163260A3 (en) Chimpanzee adenovirus vaccine carriers
CA2253632A1 (en) Compositions and methods for treating cancers and pathogen infections using antigen-presenting cells loaded with rna
EP0790835A4 (en) SPECIFIC CANCER IMMUNOTHERAPY WITH A LIVE RECOMBINANT BACTERIAL VACCINE VECTOR
WO2001053463A3 (en) COMPOUNDS AND METHODS FOR PREVENTION AND TREATMENT OF HER-2/neu ASSOCIATED MALIGNANCIES
EP0978566A3 (en) Chimaeric adenoviruses
WO1998037095A3 (en) Recombinant pox virus for immunization against muc1 tumor-associated antigen
MXPA05010255A (en) Dna vaccines against tumor growth and methods of use thereof.
CA2522812A1 (en) Hla-a2 tumor associated antigen peptides and compositions
WO2004041065A3 (en) METHODS FOR PROPHYLAXIS AND TREATMENT OF HER-2/neu TUMORS
WO2004012681A3 (en) Cancer vaccines containing epitopes of oncofetal antigen
WO2005019435A8 (en) Anti-cancer vaccines
WO2004022590A3 (en) Immunogenic muc1 glycopeptides
KR20090047289A (en) Exosomes and Cancer Vaccine Compositions Containing the Same
CA2532460A1 (en) Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof
MXPA01003240A (en) Mammaglobin, a secreted mammary-specific breast cancer protein.
CN102154223A (en) Recombinant adenovirus carrying fusion protein gene and its preparation method and application
Kim et al. Modification of CEA with both CRT and TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination
CA2254082A1 (en) Metastatic colorectal cancer vaccine
Klostermann et al. Modification of the human allergic immune response by allergen-DNA–transfected dendritic cells in vitro
Hellstrom et al. Novel approaches to therapeutic cancer vaccines
WO2000052045A3 (en) Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
Welters et al. Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour model
Behboudi et al. Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP